000			02103 a2200577 4500
005			20250513110102.0
264		0	_c19970404
008			199704s 0 0 eng d
022			_a1040-8746
024	7		_a10.1097/00001622-199611000-00007 _2doi
040			_aNLM _beng _cNLM
100	1		_aKennedy, M J
245	0	0	_aMetastatic breast cancer. _h[electronic resource]
260			_bCurrent opinion in oncology _cNov 1996
300			_a485-90 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAdenine
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aAntibodies, Neoplasm _xtherapeutic use
650	0	4	_aAntimetabolites, Antineoplastic _xtherapeutic use
650	0	4	_aAntineoplastic Agents, Phytogenic _xtherapeutic use
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aAromatase Inhibitors
650	0	4	_aBone Neoplasms _xdrug therapy
650	0	4	_aBreast Neoplasms _xdrug therapy
650	0	4	_aClinical Trials as Topic
650	0	4	_aClinical Trials, Phase II as Topic
650	0	4	_aDeoxycytidine _xanalogs & derivatives
650	0	4	_aDiphosphonates _xtherapeutic use
650	0	4	_aDocetaxel
650	0	4	_aDoxorubicin _xadministration & dosage
650	0	4	_aEnzyme Inhibitors _xtherapeutic use
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aImides _xtherapeutic use
650	0	4	_aIntercalating Agents _xtherapeutic use
650	0	4	_aIsoquinolines _xtherapeutic use
650	0	4	_aNaphthalimides
650	0	4	_aNeoplasm Metastasis
650	0	4	_aNeoplasm Proteins _xantagonists & inhibitors
650	0	4	_aOrganophosphonates
650	0	4	_aPaclitaxel _xadministration & dosage
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aSalvage Therapy
650	0	4	_aTaxoids
650	0	4	_aTopoisomerase II Inhibitors
650	0	4	_aTreatment Outcome
650	0	4	_aGemcitabine
773	0		_tCurrent opinion in oncology _gvol. 8 _gno. 6 _gp. 485-90
856	4	0	_uhttps://doi.org/10.1097/00001622-199611000-00007 _zAvailable from publisher's website
999			_c8963191 _d8963191